Metronomic capecitabine plus aromatase inhibitor as initial therapy in HR-positive HER2-negative metastatic breast cancer: a low-cost and easily implementable option.
Saved in:
| Title: | Metronomic capecitabine plus aromatase inhibitor as initial therapy in HR-positive HER2-negative metastatic breast cancer: a low-cost and easily implementable option. |
|---|---|
| Authors: | Narvaez D; Breast Cancer Department, Alexander Fleming Institute, Buenos Aires, Argentina., Parkinson GT; Stanford Healthcare, Stanford, CA, USA., Graff SL; Brown University Health Cancer Institute, Providence, RI, USA; Legorreta Cancer Center at Brown University, Providence, RI, USA. |
| Source: | Chinese clinical oncology [Chin Clin Oncol] 2025 Dec; Vol. 14 (6), pp. 79. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: AME Publishing Company Country of Publication: China NLM ID: 101608375 Publication Model: Print Cited Medium: Internet ISSN: 2304-3873 (Electronic) Linking ISSN: 23043865 NLM ISO Abbreviation: Chin Clin Oncol Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2304-3873 |
|---|---|
| DOI: | 10.21037/cco-25-82 |
